FIG. 1.
Ex vivo IFN-γ ELISPOT assay responses. (A) Acute-phase responses to wild-type Tat28-35SL8 peptide (crosses) and four variant peptides, S1P (squares), T2I (triangles), S5L (diamonds), and L8P (circles). Four Mamu-A*01+ animals were infected with SIVmac239, and PBMC were isolated at 17 and 31 days postinfection for use in this assay. Each peptide was titrated over a 7-log range of concentrations, from 10 μM down to 10 pM, and assayed in triplicate. Average numbers of spots per well are shown, with error bars representing the standard deviation. Day 17 ELISPOT assay results are shown for three animals. Day 31 results are shown for a fourth animal (rh2123), as its unusually large SL8-specific response was out of the range quantifiable by the ELISPOT assay on day 17. (B) Chronic-phase responses in Mamu-B*17+ animal 98016 to wild-type Nef165-173IW9 and three variant peptides, Nef IW9 (crosses), I1T (circles), I1A (squares), and I1T+T6M (diamonds).